Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer - PubMed (original) (raw)

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

M E L van der Burg et al. Br J Cancer. 2002.

Free PMC article

Abstract

We investigated the potential of weekly cisplatin and daily oral etoposide followed by oral etoposide maintenance therapy in patients with platinum-refractory ovarium cancer. One hundred and seven patients were entered on the study, 98 patients completed the induction therapy consisting of cisplatin at either 50 or 70 mg m(-2) weekly for six administrations plus oral etoposide at a dose of 50 mg daily. Of these 98 patients, 38 had a platinum treatment-free interval of more than 12 months, 32 had an interval between 4 and 12 months, and 28 had progressed during or within 4 months after last platinum therapy. We assessed response rates and time to progression, and also response duration and survival. Analyses were done on the 98 evaluable patients. All 107 patients were considered evaluable for toxicity. Of the 38 patients with a treatment-free interval of more than 12 months, 92% responded, with 63% complete responses. The median progression-free survival in these patients was 14 months, and the median survival was 26 months. Of the 32 patients with an interval of 4-12 months, 91% responded, with 31% complete responses, a median progression-free interval of 8 and a median overall survival of 16 months. Of the 28 patients with platinum-refractory disease, 46% as yet responded, with 29% complete responses, median progression-free interval of 5 and an overall survival of 13 months. Haematologic and non-haematologic, particularly renal toxicity and neurotoxicity, were notably mild. We conclude that this intensive regimen of weekly cisplatin plus daily etoposide is highly effective and well tolerated in patients with ovarian cancer relapsing after conventional platinum-based combination chemotherapy, including patients who have progressed during or within 4 months after platinum treatment.

PubMed Disclaimer

Figures

Figure 1

Figure 1

PFS according to platinum sensitivity.

Figure 2

Figure 2

Survival according to platinum sensitivity.

Comment in

Similar articles

Cited by

References

    1. BerekJSBertelsenKdu BoisABradyMFCarmichaelJEisenhauerEAGoreMGrenmanSHamiltonTCHansenSWHarperPGHorvathGKayeSBLuckHJLundBMcGuireWPNeijtJPOzolsRFParmarMKPiccart-GebhartMJvan RijswijkRRosenbergPRustinGJSessaCWillemsePH1998Advanced epithelial ovarian cancer: 1998 consensus statement Ann Oncol 10S87S92
    1. BolisGScarfoneGLuchiniLFerrarisCZanaboniFPrestiMGiardinaGVillaAParazziniF1994Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated and with a cisplatin or carboplatin-based regimen Eur J Cancer 30A17641768 - PubMed
    1. ChambersSKChambersJTKohornEISchwartzPE1987Etoposide plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer Gynecol Oncol 27233240 - PubMed
    1. de WitRvan der BurgMELvan der GaastALogmansAStoterGVerweijJ1994Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum containing chemotherapy Ann Oncol 5656657 - PubMed
    1. EisenhauerEAten Bokkel HuininkWSwenertonKDGianniLMylesJvan der BurgMEKerrIVermorkenJBBuserKColomboN1994European-Canadian randomised trial of Taxol in relapsed ovarian cancer: High vs low and long vs short infusion J Clin Oncol 1226542666 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources